Buy Mekinist from Canada
Mekinist (Trametinib)
From$2999
$7650
Mekinist Trametinib
Select product strength & quantity:
Select product strength & quantity:
Prescription Required
Ships within 4-10 Business Days
Express Ships from Canada
Product of Canada

Brief Overview

Mekinist, with the generic name trametinib, is a medication used in cancer treatment, particularly for melanoma, non-small cell lung cancer (NSCLC), thyroid cancer, solid tumors, and low-grade glioma with BRAF mutations. It belongs to a class of medications called kinase inhibitors and works by blocking the action of an abnormal protein that signals cancer cells to multiply, thereby helping to stop the spread of cancer cells.

Role in Treating Cancer

Mekinist is often prescribed when the cancer has spread to other parts of the body, when surgery is not an option, or to prevent the cancer from returning after surgery. It is particularly effective in cancers with specific genetic markers, such as BRAF mutations, and is used alone or in combination with other medications like dabrafenib (Tafinlar) for enhanced effectiveness.

What is Mekinist?

Mekinist is used to treat various types of cancer, including melanoma, NSCLC, and thyroid cancer. It is also used for certain types of solid tumors in adults and children aged 6 years and older, and for a specific type of glioma in children aged 1 year and older. As a kinase inhibitor, Mekinist targets and blocks the action of proteins that contribute to the growth and spread of cancer cells.

Trametinib, the active ingredient in Mekinist,  is a selective MEK inhibitor, specifically targeting MEK1 and MEK2, which are part of the MAPK pathway.is part of the multikinase inhibitors drug class. These drugs target multiple kinases, which are enzymes that play a key role in the growth and spread of cancer cells. By inhibiting these enzymes, Mekinist helps to slow down or stop the progression of cancer.

How it Works in the Body

Mekinist works by targeting specific kinases involved in the growth and spread of cancer cells. BlockingBy blocking these kinases, it prevents the cancer cells from multiplying and spreading, thereby helping to control the disease. Mekinist is particularly effective in cancers that have specific genetic mutations, making it a targeted therapy for these conditions.

How to Use Mekinist

Indications and Usage

Mekinist is indicated for the treatment of melanoma, NSCLC, thyroid cancer, certain solid tumors, and a specific type of glioma in children. It is used in patients whose cancer has specific genetic markers, such as BRAF mutations, and is often given when the cancer is advanced, cannot be removed by surgery, or to prevent recurrence after surgery.

Administration and Dosage

Mekinist (trametinib) is administered orally and is available in tablet form. The recommended dosage for adult patients is 2 mg taken once daily. It should be taken at least 1 hour before or 2 hours after a meal to ensure optimal absorption. For pediatric patients, the dosage is based on body weight. It’s crucial for patients to follow their prescribed dosage and not adjust it without consulting their healthcare provider.

Instructions for Missed Doses

If a dose of Mekinist is missed, and it’s less than 12 hours until the next dose, the missed dose should be skipped, and the next dose should be taken at the regular time. Patients should not take two doses at the same time to make up for a missed dose. Consistency in medication adherence is key tofor the effectiveness of Mekinist.

Storage Information

Proper Storage Conditions

Mekinist tablets should be stored in a refrigerator at a temperature between 2°C to 8°C (36°F to 46°F). They should not be frozen and should be kept in their original container to protect them from light and moisture. It’s important to keep Mekinist out of reach of children.

Handling and Disposal

Mekinist should be handled with care, especially when being prepared for administration. Any unused or expired medication should be disposed of properly, following guidelines for disposing of prescription drugs. Patients should consult their pharmacist or local waste disposal company for proper disposal methods.

Potential Risks and Benefits

Benefits of Mekinist

Mekinist is beneficial for treating various types of cancer, especially those with BRAF V600E or V600K mutations. It has shown effectiveness in slowing the progression of these cancers and, in some cases, reducing the size of tumors. Mekinist can be a crucial part of a cancer treatment regimen, offering hope to patients with advanced or inoperable tumors.

Risks and Precautions

While Mekinist is an effective cancer treatment, it comes with potential risks. Common side effects include skin rash, diarrhea, and fatigue. More serious risks include heart problems, eye problems, and severe skin reactions. Patients should be monitored for these side effects and report any unusual symptoms to their healthcare provider. Mekinist is not recommended for patients with colorectal cancer due to known intrinsic resistance to BRAF inhibition.

Contraindications

Mekinist should not be used in patients with a known hypersensitivity to trametinib or any of its components. It should also be used with caution in patients with a history of heart problems or those who have conditions that could be exacerbated by the side effects of Mekinist.

Mekinist is a significant medication for the treatment of various cancers, particularly those with specific genetic mutations. Patients should adhere to their prescribed dosage and schedule, store the medication properly, and be aware of its potential side effects and risks. Regular monitoring and communication with healthcare providers are essential for managing these risks effectively.

Notable Benefits and Limitations

The primary benefit of Mekinist is its ability to target specific cancer cells, making it an effective treatment for cancers with certain genetic mutations. However, its use is limited to patients with these specific genetic markers. Mekinist may cause serious side effects, and its effectiveness can vary based on individual patient factors.

Age Restrictions, if Any

Mekinist is used in adults and children aged 6 years and older for certain types of solid tumors and in children aged 1 year and older for a specific type of glioma. Its safety and effectiveness in younger children have not been established.

This expanded content provides a comprehensive understanding of Mekinist, its role in cancer treatment, how it works, and key information for patients and healthcare providers.

Side Effects

Common Side Effects

Mekinist (trametinib) is associated with several common side effects, which are generally manageable but can impact the quality of life. These include skin rash, diarrhea, and fatigue, which are often the most frequently reported. Patients may also experience headaches, cough, and shortness of breath. Gastrointestinal issues like nausea, vomiting, and abdominal pain are common, as well as peripheral edema (swelling of the hands, ankles, or feet). While these side effects are typically not severe, they can be bothersome and should be monitored. It’s important for patients to communicate any persistent or bothersome side effects to their healthcare provider.

Serious Side Effects

Serious side effects from Mekinist, though less common, can be significant and require immediate medical attention. These include heart problems, such as decreased heart function and heart failure, and lung issues like interstitial lung disease or pneumonitis. Patients may also experience severe skin reactions, including rash and acneiform dermatitis. There is a risk of retinal vein occlusion, which can lead to vision changes. Patients should be aware of these risks and seek prompt medical care if they experience symptoms indicative of these serious side effects.

Allergic Reactions

Allergic reactions to Mekinist are rare but can occur. Mild allergic reactions can manifest as skin rash, itchiness, and flushing. More severe allergic reactions, though uncommon, can include swelling under the skin, especially in the eyelids, lips, hands, or feet, and swelling of the tongue, mouth, or throat, leading to breathing difficulties. These severe reactions are medical emergencies and require immediate attention.

Drug Interactions

Interactions with Other Medications

Mekinist can interact with several other medications, which can affect how it works or increase the risk of side effects. These interactions include certain medications that affect liver enzyme activity, which can alter the removal of Mekinist from the body. Patients should inform their healthcare provider of all medications, supplements, and over-the-counter drugs they are taking.

Managing Drug Interactions

To manage these interactions, healthcare providers may adjust dosages, change medications, or closely monitor the patient. It’s important for patients to follow their doctor’s instructions and not to start or stop any medication without consulting their healthcare provider.

Warnings and Precautions

Precautions for Specific Populations

Patients with certain pre-existing conditions should exercise caution when using Mekinist. Those with an infection in or around the eye, increased eye pressure, or a history of allergic reactions to Mekinist should discuss these issues with their healthcare provider. The decision to use Mekinist in these cases will depend on a careful evaluation of the risks and benefits.

Pregnancy and Breastfeeding

The safety of Mekinist during pregnancy and breastfeeding is not well established. Pregnant women should only use Mekinist if absolutely necessary, and breastfeeding women should discuss the potential risks with their healthcare provider. It is not known if Mekinist passes into breast milk.

Other Considerations

Patients should discuss their complete health history with their healthcare provider before starting Mekinist. This includes any eye infections, increased eye pressure, or previous allergic reactions to Mekinist. Alternative treatments may be considered for patients for whom Mekinist is not suitable.

In summary, while Mekinist is an effective treatment for certain cancers, patients should be aware of its potential side effects, drug interactions, and the precautions necessary for its safe use. Regular monitoring and open communication with a healthcare provider are key to managing these risks effectively.

Clinical Studies and Research on Mekinist

Overview of Clinical Trials

Mekinist (trametinib) has undergone extensive clinical trials to evaluate its effectiveness in treating various types of cancer, particularly melanoma and non-small cell lung cancer (NSCLC) with specific genetic mutations. These trials have focused on assessing the drug’s ability to inhibit the growth of cancer cells and improve survival rates in patients.

Key Findings from Clinical Trials

Clinical trials have demonstrated that Mekinist, particularly when used in combination with other targeted therapies like dabrafenib, can significantly improve outcomes in patients with melanoma and NSCLC that have specific genetic mutations, such as BRAF V600E or V600K. The trials have shown that this combination can lead to a reduction in tumor size and an extension in progression-free survival compared to traditional chemotherapy.

Long-Term Efficacy and Safety Data

Long-term data from these trials indicate that Mekinist can be an effective long-term treatment option for certain cancers, with a manageable safety profile. Regular monitoring for side effects and adjustments in treatment regimens are essential for optimizing patient outcomes.

Patient Information and Instructions

Understanding Mekinist Treatment

Patients prescribed Mekinist should understand that it is a targeted therapy used to treat cancers with specific genetic markers. It’s important to take the medication exactly as prescribed by the healthcare provider and to be aware of the potential side effects and how to manage them.

Instructions for Use

Mekinist should be taken once daily, on an empty stomach, either one hour before or two hours after a meal. The tablets should be swallowed whole with a full glass of water. Consistency in taking the medication at the same time each day is important for its effectiveness.

Managing Side Effects and Concerns

Patients should be informed about the common and serious side effects of Mekinist and advised to contact their healthcare provider if they experience any severe or unusual symptoms. Regular follow-up appointments are necessary to monitor the patient’s response to the treatment and to check for any side effects.

In summary, clinical studies have shown Mekinist to be an effective treatment for certain types of cancer, with a well-established safety profile. Patients receiving Mekinist should be well-informed about their treatment, adhere to their medication schedule, and maintain regular communication with their healthcare provider to ensure the best possible outcomes.

Frequently Asked Questions

Mekinist is a kinase inhibitor medication used to treat patients with melanoma, non-small cell lung cancer (NSCLC), anaplastic thyroid cancer (ATC), and other solid tumors that have specific BRAF V600E or V600K mutations. It is particularly effective for metastatic or unresectable cancers and is often used in combination with other cancer treatments.

Mekinist is administered orally in tablet form. The recommended dosage for adults is 2 mg once daily, taken at least 1 hour before or 2 hours after a meal. For pediatric patients, the dosage is based on body weight. It’s important to follow the prescribed dosage and timing for optimal effectiveness.

Common side effects of Mekinist include skin issues like acne and dry skin, gastrointestinal problems such as diarrhea and abdominal pain, swelling in the limbs, high blood pressure, bleeding, fever, fatigue, cough, headache, joint and muscle pain, and night sweats. These side effects are generally manageable but should be monitored.

Mekinist is not a cure for cancer but is used to treat specific types of cancer effectively. It can significantly slow the progression of the disease and, in some cases, reduce the size of tumors. Continuous treatment is usually necessary to maintain its benefits.

Mekinist can cause fetal harm and is not recommended during pregnancy. Women of childbearing potential should use effective contraception during treatment and consult their doctor if they become pregnant during treatment. The risks and benefits should be carefully weighed.

Mekinist, especially when used in combination with other medications like dabrafenib, has shown significant effectiveness in treating melanoma with BRAF V600E or V600K mutations. It has been shown to improve survival rates and reduce tumor size in many patients.

If you miss a dose of Mekinist and it’s less than 12 hours until the next dose, skip the missed dose and take the next dose at the regular time. Do not take two doses at the same time. Consistency in medication adherence is crucial.

Long-term side effects of Mekinist can include increased risk of developing new primary malignancies, hemorrhage, cardiomyopathy, and ocular toxicities. Regular monitoring by a healthcare professional is essential to detect and manage these potential long-term effects.

Mekinist is approved for use in pediatric patients aged 1 year and older for certain conditions. The dosage for pediatric patients is based on body weight. Safety and effectiveness in younger children have not been established.

Mekinist works by inhibiting the activity of certain proteins involved in the growth and spread of cancer cells. Specifically, it targets the MEK proteins, which are part of a signaling pathway that contributes to cell proliferation and survival.

Patients using Mekinist should be aware of the potential for serious side effects and report any unusual symptoms to their healthcare provider. Regular follow-up appointments are necessary to monitor the patient’s response to the treatment and to check for any side effects.

Mekinist can cause dizziness and blurred vision in some patients. It’s recommended to avoid driving or operating heavy machinery until you know how Mekinist affects you.

As of now, there is no generic version of Mekinist available. Mekinist is a patented medication, and a generic version would only become available after the patent expires.

The duration of treatment with Mekinist varies depending on the individual’s response and the specific cancer being treated. Some patients may require long-term treatment with regular doses to maintain control over their condition.

Risks associated with Mekinist treatment include serious side effects like heart problems, lung issues, severe skin reactions, and vision changes. Patients should be monitored for these side effects and report any severe or unusual symptoms immediately.

Mekinist is often used in combination with other cancer medications, particularly dabrafenib, for enhanced effectiveness. However, it’s important to inform your healthcare provider about all medications you’re taking to manage potential interactions.

The cost of Mekinist treatment can be high and varies based on insurance coverage, geographic location, and dosage requirements. Patients should consult with their insurance provider and healthcare provider to understand the cost and explore any available financial assistance programs.

Mekinist is a targeted therapy that specifically inhibits the MEK proteins, which are part of a signaling pathway involved in cancer cell growth. This targeted approach can lead to fewer side effects and more effective treatment compared to traditional chemotherapy.

Allergic reactions to Mekinist are rare but can occur. Symptoms can range from mild (such as skin rash and itchiness) to severe (such as swelling and difficulty breathing). Patients should seek immediate medical attention if they experience signs of a severe allergic reaction.

Before starting Mekinist, discuss your complete medical history, including any previous cancer treatments and surgeries, with your healthcare provider. It’s also important to mention any allergies, current medications, and overall health status to assess the suitability of Mekinist for your condition.

Disclaimer

Pharma Giant provides medical information to help you better understand medications and medical conditions.This content is for informational use only and does not replace advice from a licensed medical practitioner. Consult your doctor or pharmacist before starting or changing any medication. All our partners follow strict safety standards set by their country’s health authorities to make sure you receive safe and high-quality medications.

Have a prescription?

Order Mekinist online today and enjoy a host of benefits, including:

 Customer Reviews
  • Cost Savings: Buy Mekinist at LOWER PRICES compared to the US
  • Bulk Order Discounts: Enjoy additional savings with bulk orders of Mekinist (up to 90-day supply)
  • Reliable Express Shipping: Fast and discreet delivery shipped directly to your doorstep
  • Exceptional Customer Service: Have a question? We’re delighted to help via live chat, email, or phone
  • Easy & Secure Ordering: Seamless online or phone ordering at 1-888-513-2294
  • SAVE 10% on first order with coupon code: PGSAVE10

Price Match Guarantee

Price Match Guarantee

We are committed to providing fair, competitive pricing on all medications. If you find a lower price on the same product at another verified Canadian online pharmacy, we’ll match it.

Eligibility Criteria

  • The pharmacy must be a licensed Canadian online pharmacy with a verifiable address.
  • The competitor’s price must be current and active (not from a past or future promotion).
  • The product must be identical in strength, pack size, quantity, manufacturer, and country of origin.
  • Requests must be submitted before placing an order — adjustments cannot be made after purchase.
  • Price matching does not apply to used or expired products.
  • Requests can be submitted via live chat or phone prior to completing your order.

Note: Price matching does not currently apply to Mounjaro® , Ozempic® or Saxenda®. However, this policy may be updated in the future.
Kenneth Fill, PharmD, MBA Fill

Kenneth Fill, PharmD, MBA, is a clinical pharmacist specialist and medical writer with a strong background in ambulatory care, pharmacogenomics, and medical content development. Based in the state of Michigan, he provides expert guidance on chronic disease state management. Kenneth completed his PharmD and MBA at the University of Toledo and pursued post-graduate residency training in ambulatory care and community-based pharmacy. His diverse background also includes academic detailing, clinical education, and interdisciplinary collaboration to enhance patient outcomes.